Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol

Area of Science:

• Endocrinology
• Virology
• Public Health

Background:

• COVID-19 poses significant challenges to healthcare systems globally.
• Emerging SARS-CoV-2 variants and insufficient vaccination rates necessitate new therapeutic strategies.
• Drug repositioning, including the use of calcifediol, is a potential approach for COVID-19 treatment.

Purpose of the Study:

• To review the association between COVID-19 and the vitamin D endocrine system (VDES).
• To explore the potential therapeutic benefits of calcifediol in managing COVID-19.
• To propose optimal dosing strategies for calcifediol in early-stage COVID-19 patients.

Main Methods:

• Review of existing literature on COVID-19, VDES, and calcifediol.
• Analysis of the proposed mechanisms of VDES/VDR stimulation in modulating COVID-19 pathology.
• Evaluation of pilot and observational studies on high-dose calcifediol interventions.

Main Results:

• VDES/VDR stimulation may enhance innate immunity and modulate the hyperinflammatory response in COVID-19.
• Calcifediol may reduce the risk of ARDS, ICU admission, mechanical ventilation, and mortality.
• High-dose calcifediol demonstrated significant reductions in ICU admission and mortality rates in pilot studies.

Conclusions:

• Calcifediol offers a promising therapeutic option for COVID-19 by rapidly correcting vitamin D deficiency.
• Early intervention with calcifediol, potentially alongside antiviral agents, is recommended for all COVID-19 patients.
• Optimizing serum 25OHD levels through calcifediol may mitigate severe COVID-19 complications.